196 related articles for article (PubMed ID: 19552546)
21. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
22. Three levels face centered central composite design of colon targeted micro-particulates system of celecoxib: screening of formulations variables and in vivo studies.
Nandy BC; Verma V; Dey S; Mazumder B
Curr Drug Deliv; 2014; 11(5):621-35. PubMed ID: 24844925
[TBL] [Abstract][Full Text] [Related]
23. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.
Ventura CA; Tommasini S; Falcone A; Giannone I; Paolino D; Sdrafkakis V; Mondello MR; Puglisi G
Int J Pharm; 2006 May; 314(1):37-45. PubMed ID: 16581211
[TBL] [Abstract][Full Text] [Related]
24. Semisolid topical formulations containing nimesulide-loaded nanocapsules, nanospheres or nanoemulsion: development and rheological characterization.
Alves PM; Pohlmann AR; Guterres SS
Pharmazie; 2005 Dec; 60(12):900-4. PubMed ID: 16398265
[TBL] [Abstract][Full Text] [Related]
25. Employment of Alginate Floating
Abdul Rasool BK; Khalifa A; Abu-Gharbieh E; Khan R
Biomed Res Int; 2020; 2020():1879125. PubMed ID: 32596281
[TBL] [Abstract][Full Text] [Related]
26. Solubility enhancement of celecoxib using beta-cyclodextrin inclusion complexes.
Rawat S; Jain SK
Eur J Pharm Biopharm; 2004 Mar; 57(2):263-7. PubMed ID: 15018983
[TBL] [Abstract][Full Text] [Related]
27. Studies on the applicability of tamarind kernel powder as a carrier in the dissolution enhancement of poorly water soluble drug, celecoxib.
Babu GV; Gowrisankar V; Himasankar K; Murthy KV
Boll Chim Farm; 2003; 142(2):76-82. PubMed ID: 12705095
[TBL] [Abstract][Full Text] [Related]
28. Preparation of celecoxib-dimethyl-beta-cyclodextrin inclusion complex: characterization and in vitro permeation study.
Ventura CA; Giannone I; Paolino D; Pistarà V; Corsaro A; Puglisi G
Eur J Med Chem; 2005 Jul; 40(7):624-31. PubMed ID: 15935897
[TBL] [Abstract][Full Text] [Related]
29. Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug.
Tran TT; Tran PH; Lee BJ
Eur J Pharm Biopharm; 2009 May; 72(1):83-90. PubMed ID: 19141319
[TBL] [Abstract][Full Text] [Related]
30. Development and bioavailability assessment of ramipril nanoemulsion formulation.
Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M
Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045
[TBL] [Abstract][Full Text] [Related]
31. Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.
Estracanholli EA; Praça FS; Cintra AB; Pierre MB; Lara MG
AAPS PharmSciTech; 2014 Dec; 15(6):1468-75. PubMed ID: 24980082
[TBL] [Abstract][Full Text] [Related]
32. Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption.
Shi Y; Gao P; Gong Y; Ping H
Mol Pharm; 2010 Oct; 7(5):1458-65. PubMed ID: 20704265
[TBL] [Abstract][Full Text] [Related]
33. Formation of celecoxib nanoparticles from volatile microemulsions.
Margulis-Goshen K; Kesselman E; Danino D; Magdassi S
Int J Pharm; 2010 Jun; 393(1-2):230-7. PubMed ID: 20403417
[TBL] [Abstract][Full Text] [Related]
34. Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment.
Bali V; Ali M; Ali J
Int J Pharm; 2011 Jan; 403(1-2):46-56. PubMed ID: 20969935
[TBL] [Abstract][Full Text] [Related]
35. Preparation and evaluation of celecoxib transdermal patches.
Jayaprakash S; Halith SM; Firthouse PM; Yasmin ; Nagarajan M
Pak J Pharm Sci; 2010 Jul; 23(3):279-83. PubMed ID: 20566440
[TBL] [Abstract][Full Text] [Related]
36. Skin permeation mechanism of aceclofenac using novel nanoemulsion formulation.
Shakeel F; Baboota S; Ahuja A; All J; Shafiq S
Pharmazie; 2008 Aug; 63(8):580-4. PubMed ID: 18771006
[TBL] [Abstract][Full Text] [Related]
37. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
38. Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy.
Zhao P; Jiang H; Jiang T; Zhi Z; Wu C; Sun C; Zhang J; Wang S
Eur J Pharm Sci; 2012 Apr; 45(5):639-47. PubMed ID: 22251657
[TBL] [Abstract][Full Text] [Related]
39. Potential of nanoemulsions for intravenous delivery of rifampicin.
Ahmed M; Ramadan W; Rambhu D; Shakeel F
Pharmazie; 2008 Nov; 63(11):806-11. PubMed ID: 19069240
[TBL] [Abstract][Full Text] [Related]
40. Solid Phospholipid Dispersions for Oral Delivery of Poorly Soluble Drugs: Investigation Into Celecoxib Incorporation and Solubility-In Vitro Permeability Enhancement.
Fong SY; Martins SM; Brandl M; Bauer-Brandl A
J Pharm Sci; 2016 Mar; 105(3):1113-23. PubMed ID: 26886329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
